

FORM 2B

LISTING SUMMARY

Issuer Name: Britannia Life Sciences Inc. (the "Issuer")	Listing Statement Date: October 29, 2021			
Descriptions of securities to be listed: Common Shares				
Address: 120 Adelaide St. West, Suite 2400, Toronto, Ontario, M5H 1T1	Brief Description of the Issuer's Business: The Issuer is a diversified product testing, quality assurance, safety assessment, and regulatory compliance company, offering a broad range of complementary services to both blue-chip and small to medium sized enterprises, concentrated in the consumer packaged goods, cosmetics, household goods and nutraceutical industries. The Issuer will serve a diverse customer base including multinational companies, retailers and brands, and develop, test, validate and distribute products for its clients using its laboratory and technology platform. Upon the completion of the transaction, the Issuer expects to leverage and utilize the intellectual property of RISE Life Science Corp. ("RISE") to further develop its product and service offerings.			
Company Contact: Peter Shippen	Description of securities outstanding: Currently, there are 27,966,260 common shares of RISE. Immediately following the RTO Transaction, it is anticipated that 155,363,062 common shares of the Issuer will be outstanding.			
Phone: (416) 433-9259	Symbol: BLAB	Type: Common Shares	Number: 155,363,062	CUSIP: 11042D108
Fax: N/A	If the Listing Statement was required to be filed because an event giving rise to material information has occurred that makes the previous Statement inaccurate or misleading, briefly describe the event: N/A			
E-mail: peter@britannia.life	Dates of Press Release and Any Public Filings Concerning the Event: Press Release announcing the amendment to the letter of intent filed on SEDAR on January 21, 2021. Press Release announcing the entering into of the business combination agreement filed on SEDAR on May 3, 2021.			

			<p>Material change report regarding the entering into of the business combination agreement filed on SEDAR on May 10, 2021.</p> <p>Business Combination Agreement dated April 30, 2021 filed on SEDAR on May 10, 2021.</p> <p>Management Information Circular of RISE Life Science Corp. dated August 10, 2021 filed on SEDAR on August 18, 2021</p>	
Jurisdiction of Incorporation: Canada			<p>Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled):</p> <p>The last shareholders' meeting of RISE was held on September 8, 2021.</p>	
Website: https://britannia.life/				
Fiscal Year End: March 31 (proposed year-end of Britannia Life Sciences Inc.)				
Financial Information as at: June 30, 2021 for the Issuer and May 31, 2021 for RISE			Board of Directors:	
	<u>Current</u> <u>June 30,</u> <u>2021</u>	<u>Previous</u> <u>May 31,</u> <u>2021</u>	Name	Position
Current Assets	\$6,070,662	\$1,175,313	Peter Shippen	Director
Working Capital	\$2,216,230 ¹	\$(5,216,274)	Scott Secord	Director
Total assets	\$24,210,387	\$1,202,022	Greg Taylor	Director
Long-term liabilities	\$3,040,691	\$60,000		
Shareholders' equity	\$9,682,527	\$(5,249,565)		

¹ The working capital of the Issuer as at September 30, 2021 is \$4,204,203